The concurrent CK2 inhibition by CX-4945 efficiently attenuated the abnormalities in social interaction, indicating that targeting BRD4 or its phosphorylation status is a promising approach to reverse some of the cognitive deficits observed in FXS [102]. The gene discussed is BRD4; the disease is fragile X syndrome.